GI Oncology
From the Journals
Consider adding chemotherapy after GI surgery
Average survival rates at 3 years after surgery were 40 months for those who received adjuvant chemotherapy vs. 34 months for those who did not....
News
FDA approves nivolumab for HCC patients
Approval of nivolumab for HCC was based on tumor response rate and durability of response from the phase 1/2 Checkmate 040 trial.
News
FDA approves biosimilar to bevacizumab
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.
Latest News
Analysis: Actual cancer drug R&D costs are far less than widely publicized sum
Research and development costs for cancer drugs may be far lower than previous estimates, casting doubt on common justifications by drug companies...
Conference Coverage
Minimally invasive esophagectomy may mean less major morbidity
COLORADO SPRINGS – Shorter LOS also seen in ACS-NSQIP analysis
From the Journals
Reduced starting dose of sorafenib for HCC appears safe
The initiation of sorafenib at a reduced dosage may be a safe and reasonable strategy for some patients with hepatocellular carcinoma.
News
FDA approves nivolumab for metastatic CRC
The indication includes patients aged 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal...
From the Journals
VIDEO: Large distal nongranular colorectal polyps were most likely to contain occult invasive cancers
Location and Paris classification had primary importance.
From the Journals
Molecular subtypes predicted outcomes in gastric cancer
Genetic details of each cancer may guide treatment.
From the Journals
Blood markers can detect early pancreatic cancer
A test in development is recommended for those at high risk and those newly diagnosed with diabetes.
News
FDA approves new panel to identify mCRC patients for panitumumab treatment
The Food and Drug Administration has approved the Praxis Extended RAS Panel for the identification of metastatic colorectal cancer patients who...